Global Recombinant Protein Market - Segmented by Product (Hormone, Growth Factor, Cytokine, Antibody, Enzyme, and Other Products), Type of Application, and Geography - Growth, Trends, and Forecast (2022-2030)
The recombinant protein market is expected to register a growth rate of nearly 6.5% over the forecast period, 2018-2023. Recombinant proteins are encoded by recombinant DNA, which involves the insertion of DNA encoding that particular protein into bacterial or mammalian cells, and the protein is then purified after getting expressed in these cells. Recombinant protein is produced either by molecular cloning or through polymerase chain reaction (PCR). The prominence of recombinant proteins has been increasing tremendously for therapeutic application, owing to advancement in technologies, which further facilitates market growth by developing alternative expression technologies and enhanced cell culture systems. It is also considered to be the foundation of biomolecular research and the developing biotechnology industry. As per the geographical analysis, the North American region possesses several factors, such as well-developed research infrastructure and higher expenditure in biomedical research, which makes this market to retain dominance in this region.
Growing Prevalence of Chronic Diseases Boosts the Growth of the Recombinant Protein Market
The prevalence of chronic diseases, such as cancer, diabetes, and arthritis, are on the rise, globally, as well as the treatment of the aforementioned diseases. As per the statistics recorded by the World Health Organization (WHO), the number of people with diabetes increased to 422 million in 2014, and in 2015, approximately 1.6 million deaths were directly caused due to diabetes and its associated complications. This exponential rise presents an urgent need to establish an effective diabetes therapy, where recombinant insulin plays a major role. Arthritis is also one of the leading causes of disability among adults in the United States, where about 54 million adults have doctor-diagnosed arthritis. This huge burden of arthritis needs disease management through different recombinant proteins, thus, fueling the recombinant protein market.
Other factors contributing to the recombinant protein market are, the growing expenditure in the R&D sector, rising inclination toward biologics and biosimilars, and advanced recombinant products.
Expensive and Time-consuming Production Process Limits the Growth of the Recombinant Protein Market
Recombinant protein production is a very time-consuming procedure, which requires high maintenance. The cost of the recombinant protein produced in E. coli is around EUR 10,000–15,000/mg, this high cost thus indicates the need of alternate platform, which is expected to restrain the recombinant protein market.
Another factor limiting the growth of this market is the safety issues associated with recombinant proteins.
North America is Expected to Dominate the Recombinant Protein Market over the Forecast Period
North America is expected to lead the global recombinant protein market, owing to the increasing expenditure in research. The United States is anticipated to witness highest growth, owing to the largest concentration of world-class research universities and academic medical centers. The R&D spending of the United States is around 2.7% of its gross domestic products (GDP). In 2014, The United States was leading the R&D investments in biotechnology, and since then, the US biotechnology research and investment has been growing at a steady rate. Development of new products and collaboration activities of biotechnology companies are likely to boost the growth of the recombinant protein market.
Thus, the increasing expenditure and major focus on R&D are expected to generate high opportunities for the growth of the North American recombinant protein market.
Key Developments in the Recombinant Protein Market
• Jul 2018: Abcam Merck collaboration produced PD-L1 antibody for immuno-oncology research.
• Jan 2018: Abcam signed exclusive license agreement with Roche, and under the terms of the agreement, Abcam obtained the exclusive rights to the product portfolio of Spring Bioscience Corporation in the research-use-only (RUO) field of use, comprising of 243 recombinant rabbit monoclonal antibodies.
Major Players: ABCAM PLC, ABNOVA CORPORATION, ELI LILLY AND COMPANY, ENZO LIFE SCIENCES INC., EUROGENTEC (KANEKA CORPORATION), MERCK KGAA, NOVO NORDISK AS, NOVOPROTEIN, PROSPEC-TANY TECHNOGENE LTD, R&D SYSTEMS (BIO-TECHNE), ROCHE DIAGNOSTICS, AND THERMOFISHER SCIENTIFIC among others.
Reasons to Purchase this Report
• Current and future recombinant protein market outlook in the developed and emerging markets
• Analysis of the various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure that you to get a report which suits your needs
Growing Prevalence of Chronic Diseases Boosts the Growth of the Recombinant Protein Market
The prevalence of chronic diseases, such as cancer, diabetes, and arthritis, are on the rise, globally, as well as the treatment of the aforementioned diseases. As per the statistics recorded by the World Health Organization (WHO), the number of people with diabetes increased to 422 million in 2014, and in 2015, approximately 1.6 million deaths were directly caused due to diabetes and its associated complications. This exponential rise presents an urgent need to establish an effective diabetes therapy, where recombinant insulin plays a major role. Arthritis is also one of the leading causes of disability among adults in the United States, where about 54 million adults have doctor-diagnosed arthritis. This huge burden of arthritis needs disease management through different recombinant proteins, thus, fueling the recombinant protein market.
Other factors contributing to the recombinant protein market are, the growing expenditure in the R&D sector, rising inclination toward biologics and biosimilars, and advanced recombinant products.
Expensive and Time-consuming Production Process Limits the Growth of the Recombinant Protein Market
Recombinant protein production is a very time-consuming procedure, which requires high maintenance. The cost of the recombinant protein produced in E. coli is around EUR 10,000–15,000/mg, this high cost thus indicates the need of alternate platform, which is expected to restrain the recombinant protein market.
Another factor limiting the growth of this market is the safety issues associated with recombinant proteins.
North America is Expected to Dominate the Recombinant Protein Market over the Forecast Period
North America is expected to lead the global recombinant protein market, owing to the increasing expenditure in research. The United States is anticipated to witness highest growth, owing to the largest concentration of world-class research universities and academic medical centers. The R&D spending of the United States is around 2.7% of its gross domestic products (GDP). In 2014, The United States was leading the R&D investments in biotechnology, and since then, the US biotechnology research and investment has been growing at a steady rate. Development of new products and collaboration activities of biotechnology companies are likely to boost the growth of the recombinant protein market.
Thus, the increasing expenditure and major focus on R&D are expected to generate high opportunities for the growth of the North American recombinant protein market.
Key Developments in the Recombinant Protein Market
• Jul 2018: Abcam Merck collaboration produced PD-L1 antibody for immuno-oncology research.
• Jan 2018: Abcam signed exclusive license agreement with Roche, and under the terms of the agreement, Abcam obtained the exclusive rights to the product portfolio of Spring Bioscience Corporation in the research-use-only (RUO) field of use, comprising of 243 recombinant rabbit monoclonal antibodies.
Major Players: ABCAM PLC, ABNOVA CORPORATION, ELI LILLY AND COMPANY, ENZO LIFE SCIENCES INC., EUROGENTEC (KANEKA CORPORATION), MERCK KGAA, NOVO NORDISK AS, NOVOPROTEIN, PROSPEC-TANY TECHNOGENE LTD, R&D SYSTEMS (BIO-TECHNE), ROCHE DIAGNOSTICS, AND THERMOFISHER SCIENTIFIC among others.
Reasons to Purchase this Report
• Current and future recombinant protein market outlook in the developed and emerging markets
• Analysis of the various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure that you to get a report which suits your needs
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
